IRMD

SEC source: 0001613801-25-000023 · form4-10292025_091001.xml · nonDerivative · entry 3

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,327,500

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F4 · price: This transaction was executed in multiple trades at prices ranging from $79.07 to $79.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000023 · form4-10292025_091001.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,327,558

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F3 · price: This transaction was executed in multiple trades at prices ranging from $78.00 to $78.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000023 · form4-10292025_091001.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,328,258

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $76.99 to $77.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000021 · form4-10222025_041001.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,332,500

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F3 · price: This transaction was executed in multiple trades at prices ranging from $75.22 to $75.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000021 · form4-10222025_041001.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,333,923

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $74.17 to $75.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001950129-25-000003 · form4-10152025_041001.xml · derivative · entry 2

Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,767 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On October 14, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On October 14, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001950129-25-000003 · form4-10152025_041001.xml · nonDerivative · entry 1

Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,496

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001613801-25-000019 · form4-10142025_041001.xml · nonDerivative · entry 3

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,337,500

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F4 · price: This transaction was executed in multiple trades at prices ranging from $74.05 to $74.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000019 · form4-10142025_041001.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,337,527

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F3 · price: This transaction was executed in multiple trades at prices ranging from $72.93 to $73.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000019 · form4-10142025_041001.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,339,273

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $71.65 to $72.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000017 · form4-10072025_051001.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,342,500

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

SEC source: 0001613801-25-000017 · form4-10072025_051001.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,342,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $71.25 to $72.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000015 · form4-10022025_051007.xml · nonDerivative · entry 3

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,347,500

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F4 · price: This transaction was executed in multiple trades at prices ranging from $70.93 to $71.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000015 · form4-10022025_051007.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,347,929

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F3 · price: This transaction was executed in multiple trades at prices ranging from $69.90 to $70.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000015 · form4-10022025_051007.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,351,377

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $68.86 to $69.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001613801-25-000013 · form4-09242025_040901.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,352,500

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.81 to $71.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001228621-25-000005 · form4-09252025_110901.xml · derivative · entry 1

KIANI JOE E · CIK 0001228621 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,095

Underlying: Common Stock · 2,095 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on September 23, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on September 23, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001613801-25-000010 · form4-09182025_040901.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,357,500

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F4 · price: This transaction was executed in multiple trades at prices ranging from $71.47 to $72.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001613801-25-000010 · form4-09182025_040901.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust

Disclosed balance after: 2,359,046

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.46 to $71.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-25-021209 · form4-08062025_080801.xml · nonDerivative · entry 1

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,898

F1 · price: This transaction was executed in a single trade at the stated price.

SEC source: 0001415889-25-018013 · form4-06232025_080616.xml · derivative · entry 3

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,796

Underlying: Common Stock · 5,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

F2 · derivative.exercise_date: On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F2 · derivative.expiration_date: On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-25-018013 · form4-06232025_080616.xml · nonDerivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,151

SEC source: 0001415889-25-018013 · form4-06232025_080616.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,563

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

F1 · price: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

SEC source: 0001415889-24-029269 · form4-12132024_041203.xml · derivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,008

Underlying: Common Stock · 1,811 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-029273 · form4-12132024_041210.xml · derivative · entry 2

Chiprin Jeff · CIK 0002047489 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,989

Underlying: Common Stock · 2,989 shares

Expires not disclosed

F3 · derivative.exercise_price: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.

F3 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.

F3 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.

SEC source: 0001415889-24-029273 · form4-12132024_041210.xml · derivative · entry 1

Chiprin Jeff · CIK 0002047489 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,990

Underlying: Common Stock · 2,990 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F2 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-24-029272 · form4-12132024_041208.xml · derivative · entry 1

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,008

Underlying: Common Stock · 1,811 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025 Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025 Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-029271 · form4-12132024_041207.xml · derivative · entry 1

Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,008

Underlying: Common Stock · 1,811 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-029270 · form4-12132024_041205.xml · derivative · entry 1

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,008

Underlying: Common Stock · 1,811 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-029268 · form4-12132024_041201.xml · derivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,119

Underlying: Common Stock · 5,435 shares

Expires not disclosed

F3 · derivative.exercise_price: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.

F3 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.

F3 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.

SEC source: 0001415889-24-029268 · form4-12132024_041201.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,508

Underlying: Common Stock · 5,436 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F2 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-24-028903 · form4-12102024_091209.xml · derivative · entry 4

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,197

Underlying: Common Stock · 1,196 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-028903 · form4-12102024_091209.xml · derivative · entry 3

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,751 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-028903 · form4-12102024_091209.xml · nonDerivative · entry 2

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-24-028903 · form4-12102024_091209.xml · nonDerivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,099

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-24-028902 · form4-12102024_091207.xml · derivative · entry 2

Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,197

Underlying: Common Stock · 1,196 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-028902 · form4-12102024_091207.xml · nonDerivative · entry 1

Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-24-028901 · form4-12102024_091204.xml · derivative · entry 4

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,197

Underlying: Common Stock · 1,196 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-028901 · form4-12102024_091204.xml · derivative · entry 3

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,751 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-028901 · form4-12102024_091204.xml · nonDerivative · entry 2

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,181

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-24-028901 · form4-12102024_091204.xml · nonDerivative · entry 1

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-24-028900 · form4-12102024_091201.xml · derivative · entry 4

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,197

Underlying: Common Stock · 1,196 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-028900 · form4-12102024_091201.xml · derivative · entry 3

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,751 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-028900 · form4-12102024_091201.xml · nonDerivative · entry 2

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-24-028900 · form4-12102024_091201.xml · nonDerivative · entry 1

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,804

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-25-010211 · form4a-04042025_040403.xml · nonDerivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,545

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On December 10, 2024, the reporting person timely filed a Form 4, which inadvertently overstated in column 5 the number of shares of Iradimed Corporation (the "Issuer") common stock directly owned by the reporting person following the reported transaction. No transactions regarding the Issuer's securities were omitted. This inadvertent overstatement has been corrected in this amended filing.

F1 · balance_after: On December 10, 2024, the reporting person timely filed a Form 4, which inadvertently overstated in column 5 the number of shares of Iradimed Corporation (the "Issuer") common stock directly owned by the reporting person following the reported transaction. No transactions regarding the Issuer's securities were omitted. This inadvertent overstatement has been corrected in this amended filing.

SEC source: 0001415889-24-028036 · form4-12022024_091202.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,383

F1 · price: This transaction was executed in multiple trades at prices ranging from $54.00 to $54.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-026235 · form4-11062024_041101.xml · nonDerivative · entry 1

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,234

F1 · price: This transaction was executed in multiple trades at prices ranging from $55.98 to $56.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-025137 · form4-10152024_051001.xml · derivative · entry 2

Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,767

Underlying: Common Stock · 1,767 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.expiration_date: On October 14, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-24-025137 · form4-10152024_051001.xml · nonDerivative · entry 1

Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,533

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.